{
    "output": [
        [
            "Shire",
            "COMP",
            "Decrease",
            "Revenue Target",
            "ECON_INDICATOR"
        ],
        [
            "Shire",
            "COMP",
            "Operate_In",
            "Pharmaceutical Industry",
            "SECTOR"
        ],
        [
            "Shire",
            "COMP",
            "Acquire",
            "Baxalta",
            "COMP"
        ],
        [
            "Shire",
            "COMP",
            "Has",
            "Hematology",
            "SECTOR"
        ],
        [
            "Shire",
            "COMP",
            "Impact",
            "Negative_Impact_On",
            "Stock Value",
            "FIN_INSTRUMENT"
        ],
        [
            "Shire",
            "COMP",
            "Produce",
            "Ulcerative Colitis Drug",
            "PRODUCT"
        ],
        [
            "Shire",
            "COMP",
            "Control",
            "Immunology Franchise",
            "SECTOR"
        ],
        [
            "Shire",
            "COMP",
            "Consider",
            "Spin Off",
            "CONCEPT"
        ],
        [
            "Shire",
            "COMP",
            "Evaluate",
            "Merits",
            "CONCEPT"
        ],
        [
            "Shire",
            "COMP",
            "Relate_To",
            "Hyperactivity Drugs",
            "PRODUCT"
        ],
        [
            "Shire",
            "COMP",
            "Relate_To",
            "Standalone Group",
            "COMP"
        ],
        [
            "Baxalta",
            "COMP",
            "Acquire",
            "Shire",
            "COMP"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Is_Member_Of",
            "Shire",
            "COMP"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Say",
            "Change",
            "CONCEPT"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Say",
            "Additional Competition",
            "CONCEPT"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Say",
            "Consensus Among Industry Analysts",
            "CONCEPT"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Say",
            "Revenue Had Tripled",
            "ECON_INDICATOR"
        ],
        [
            "Flemming Ornskov",
            "PERSON",
            "Say",
            "20 Billion Was A Stretch Target",
            "ECON_INDICATOR"
        ],
        [
            "Industry Analysts",
            "PERSON",
            "Say",
            "Consensus For Annual Revenue By 2020",
            "ECON_INDICATOR"
        ],
        [
            "HSBC",
            "COMP",
            "Say",
            "Reconsider 2020 Guidance",
            "CONCEPT"
        ],
        [
            "Roche",
            "COMP",
            "Report",
            "Positive Clinical Data",
            "CONCEPT"
        ],
        [
            "Roche",
            "COMP",
            "Threaten",
            "Shire Products",
            "PRODUCT"
        ],
        [
            "U.S. Regulators",
            "ORG/GOV",
            "Approve",
            "Generic Competitor",
            "PRODUCT"
        ],
        [
            "Neuroscience",
            "CONCEPT",
            "Leader",
            "Shire",
            "COMP"
        ],
        [
            "Adderall",
            "PRODUCT",
            "Owner",
            "Richwood Pharmaceutical",
            "COMP"
        ],
        [
            "Richwood Pharmaceutical",
            "COMP",
            "Acquire",
            "Shire",
            "COMP"
        ],
        [
            "Standalone Group",
            "COMP",
            "Worth",
            "$8.5 Billion",
            "ECON_INDICATOR"
        ]
    ]
}